ADIPOQ and familial pancreatic carcinoma: Our results are concordant with data from a prospective study on plasma adiponectin and pancreatic cancer risk in five US cohorts where median plasma adiponectin was lower in case subjects vs. control subjects and low prediagnostic levels of circulating adiponectin were associated with an elevated risk of pancreatic cancer [93].We also conclude that hipoadiponectinemia increases pancreatic cancer risk [94].